FDA Approves Novel Treatment for Polycythemia Vera

The FDA has approved rusfertide (Mimrylo) by Takeda Pharmaceutical and Protagonist Therapeutics for polycythemia vera, a rare blood disorder. This first-in-class medicine mimics hepcidin to regulate iron and reduce red blood cell production, addressing a significant unmet need for patients whose red blood cell levels remain high despite existing therapies. This approval offers a new therapeutic option for managing the condition.